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Background: Recent studies have highlighted associations between use of antidepres-
sant medications and coronary heart disease (CHD).Tricyclic antidepressants (TCA) are not
recommended in patients with CHD as they may increase morbidity and mortality. How-
ever, this class of antidepressants is freely prescribed in public health pharmacies, while
access to other classes of antidepressants is restricted in Brazil. Here, we examine the
associations between antidepressant use and prevalent CHD in a large cohort from Brazil.
Methods: Participants included 14,994 civil servants aged 35–74 years from the baseline
assessment of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). CHD (n=710)
included stable angina, myocardial infarction, and coronary revascularization. Univariate
(unadjusted) and multivariate (adjusted) logistic regression analyses were conducted to
estimate odds ratios and confidence intervals.
Results: After full adjustment for covariates, TCA use (n=156) was associated with a
twofold increase in prevalent CHD, relative to non-use (n=14,076). Additional sensitiv-
ity analysis revealed a threefold association for myocardial infarction (OR: 2.96, 95% CI:
1.41–6.21) and coronary revascularization (OR: 2.92, 95% CI: 1.28–6.66). There were no
significant associations between antidepressant use and stable angina pectoris.
Conclusion: Findings highlight a strong association betweenTCA use and prevalent CHD.
While the cross-sectional design is an important limitation of the present study, findings
have important implications for the treatment of cardiac patients in Brazil.
Keywords: tricyclic antidepressants, coronary heart disease, Brazil, cross-sectional design, clinical epidemiology,
TCA, CHD
INTRODUCTION
Coronary heart disease (CHD) and major depressive disorder
(MDD) are leading burdens of disease (1) and the relationship
between these disorders is bidirectional: patients with CHD have
more MDD than the general population, while those with MDD
are more likely to develop CHD (2, 3). Critically, comorbid-
ity between CHD and MDD increases risk of further morbidity
and mortality (4). Other studies have highlighted the association
between CHD and the anxiety disorders (5, 6). Antidepressant use
in patients with CHD is controversial. While use of tricyclic antide-
pressants (TCA) is not recommended (7), research indicates that
all classes of antidepressant medications may have adverse car-
diac effects (8, 9) [but see Ref. (10, 11) in regards to the selective
serotonin reuptake inhibitor, or SSRI, antidepressant class]. The
selective serotonin reuptake inhibitors are generally considered to
be the safest class of antidepressants for use in cardiac patients
(12) when needed. Here, we examine the association between
antidepressant use and prevalent CHD in a large epidemiological
cohort from Brazil.
The cardiovascular risks of TCA are well known (13). Although
initially it was believed that TCAs could suppress arrhythmias in
depressed patients with pre-existing arrhythmias, this belief was
revised more than 20 years ago (13). The TCAs are also potent
antagonists of muscarinic acetylcholine receptors (14) at the sinoa-
trial node of the heart leading to a decrease in parasympathetic
activity, disinhibition of sympathetic nervous system activity, and
tachycardia (15), which may lead to adverse cardiovascular events.
While an earlier case–control study (16) reported that TCAs
only increased the risk of myocardial infarction within the initial
28 days of antidepressant use, more recent research (17) demon-
strated that use of TCAs are associated with a 35% increased risk
of cardiovascular death over an 8-year follow-up period in ini-
tially healthy individuals. Consistent with this body of literature, a
recent consensus statement from the National Heart Foundation
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of Australia (7), a high-income country, recommends that TCA be
avoided in patients with CHD and depression.
While recommendations are helpful, they are difficult to apply
in less-developed countries. Brazil is an upper-middle-income
country facing major social challenges that may impact on the
associations between CHD and antidepressant use. We have
reported previously (18) that only 14 and 16.5% of patients in
Brazil with generalized anxiety and MDD, respectively, take anti-
depressant medication. We also observed that while SSRIs were
prescribed twice more frequently than tricyclic medications, anti-
depressant use was related to having private health insurance. TCA
are freely dispensed in public health pharmacies in Brazil, while
most of the SSRI medications are not, with the exception of fluox-
etine and, in some regions of Brazil including São Paulo, sertraline
(18, 19). (The list of medicines supplied by the Brazilian Unified
Health System, or SUS, in São Paulo is available here: http://www2.
hu.usp.br/confira-lista-de-medicamentos-do-sus/.) TCA there-
fore play an important role in treating depression, as well as
a variety of other conditions including neuropathic pain and
fibromyalgia (20) in Brazil. This context provides an important
background for the current study, which sought to determine the
associations between use of antidepressant medications and preva-
lent CHD in the Brazilian Longitudinal Study of Adult Health
(ELSA-Brasil) (21, 22) cohort. We examine associations in the
cohort at baseline to provide an important foundation for future
prospective analyses on this cohort.
MATERIALS AND METHODS
PARTICIPANTS
ELSA-Brasil is a cohort of 15,105 civil servants aged 35–74 years
enrolled between August 2008 and December 2010 at six cities
(Belo Horizonte, Porto Alegre, Rio de Janeiro, Salvador, Sao Paulo,
and Vitoria) designed to investigate the relationship between car-
diovascular diseases and diabetes, their social determinants, and
risk factors. The study design and sampling procedures of ELSA-
Brasil have been reported previously (21, 22). A total of 14,994
participants are reported here after dropping a relatively small
number of cases (n= 111) with missing data on variables that
were included in analyses.
ETHICS STATEMENT
The ethics committees of the participating universities as well as
the National Research Ethics Committee approved the research
protocol. All participants provided written informed consent after
a complete description of the study.
PSYCHIATRIC EVALUATION
Mental disorders were determined by trained interviewers using
the Portuguese version (23) of the Clinical Interview Schedule-
Revised (CIS-R) (24). This is a structured interview used for
diagnosis of common, non-psychotic psychiatric conditions in
the community. The complete CIS-R version was applied, sever-
ity scores were obtained, and common mental disorder sta-
tus (CIS-R scores ≥12), determined. Antidepressant medications
[Anatomical Therapeutic Chemical (ATC) Classification code:
N06A] included the selective serotonin reuptake inhibitors (SSRI,
ATC code: N06AB), the serotonin and noradrenaline reuptake
inhibitors (SNRIs, ATC codes: N06AX16/N06AX23/N06AX21),
the TCA (ATC code: N06AA), and other antidepressants
(N06AX22, N06AX12, N06AA21, N06AX05, N06AX11). Individ-
uals taking at least one antidepressant medicine continuously in
the past 2 weeks were classified as users.
CORONARY HEART DISEASE ASSESSMENT
Coronary heart disease (CHD) included participants with sta-
ble angina pectoris, myocardial infarction, and coronary revas-
cularization determined through questionnaire- and intensive
interview-based assessment focusing on medical history. All prior
CHD were self-referred by the patients during the structured inter-
view. For the current analysis, prevalent CHD was defined as
a prior history of a physician diagnosed myocardial infarction,
a prior percutaneous coronary intervention including balloon
angioplasty with or without stent placement, a prior surgical revas-
cularization consisting of either arterial or venous grafts and the
history of stable angina as defined by a physician taking care of the
participant prior to the inclusion in the ELSA study. The outcome
of coronary revascularization was defined as either a percutaneous
coronary intervention or a surgical revascularization as previously
described.
STATISTICAL ANALYSIS
Statistical analysis was conducted using IBM SPSS Statistics Ver-
sion 21. Participant characteristics were examined using indepen-
dent samples t -tests and one-way analyses of variance (ANOVA)
for contrasts involving continuous dependent measures, and χ2
statistics for categorical variables. Degrees of freedom were cor-
rected when Levene’s Test for Equality of Variances was violated.
Tukey’s HSD is reported to correct for multiple comparisons and
aid interpretation of ANOVA’s, while standardized residuals (z-
scores) were used to help interpret chi-square tests on larger
contingency tables [as per Ref. (25)].
A series of univariate and multivariate, binary, logistic regres-
sion analyses were then used to estimate the odds ratios and 95%
confidence intervals for the association between antidepressant
use as the independent variable (IV) and prevalent CHD (no, yes)
as the dependent variable (DV), before and after adjustment for
covariates. Unadjusted (univariate) and adjusted (multivariate)
analyses were also conducted on specific classes of antidepres-
sants (IV) including the SSRIs, the SNRIs, tricyclic medications
and others, and prevalent CHD (no, yes) (DV). Unadjusted uni-
variate, binary, logistic regression analyses (model 1) were con-
ducted on antidepressant use (no versus yes), as well as classes of
antidepressants, with no other predictors. Adjusted multivariate
analyses (model 2) involved binary logistic regression analysis in
which covariates were entered into the first block using the enter
method, and antidepressant use was entered into the second (final)
block, a technique known as sequential logistic regression analy-
sis. Covariates included age, sex, education (less than high-school,
high-school, university), smoking status (never, past/current),
body mass index (BMI; weight in kilograms divided by height in
meters squared), hypertension (systolic blood pressure ≥140 mm
Hg, or diastolic blood pressure ≥90 mm Hg, or use of antihy-
pertensive medications), diabetes mellitus (DM) (self-reported
or fasting blood glucose ≥126 mg/dL, 2-h oral glucose tolerance
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test ≥200 mg/dL, or glycated hemoglobin ≥6.5%), and severity
of mood and anxiety disorders. Sequential, logistic regression
analysis is a common approach that allows for the independent
contribution of antidepressant use over and above covariates to be
determined (26). Statistics from multivariate analyses are reported
for the overall model and block (after adjusting for covariates).
The block statistic indicates whether or not the IV of inter-
est (antidepressant use/class) is significantly associated with the
dependent measure, CHD. Sensitivity analyses were conducted for
specific CHD events to determine the consistency of associations
across distinct categories of CHD. Sensitivity analyses involved
sequential, binary logistic regression analysis in which covariates
were entered into block 1 using the enter method, followed by
antidepressant use in block 2 (as per model 2).
RESULTS
PARTICIPANT CHARACTERISTICS
Table 1 summarizes participant characteristics by CHD status,
while Table 2 presents participant characteristics according to
antidepressant use. Prevalent CHD was characterized by older
age, more men, less education, more smokers, higher BMI, more
individuals with DM, hypertension and common mental disor-
der, higher CIS-R score, and antidepressant use. Antidepressant
use was characterized by older age, more women, more education,
more smokers, more individuals with CHD and common mental
disorder, and higher CIS-R score. Table 3 provides a more detailed
breakdown of participant characteristics by antidepressant class.
Notably, TCA use is characterized by more women, fewer individu-
als with college-level education and more with CHD and common
mental disorder, and a higher CIS-R score.
ASSOCIATION BETWEEN ANTIDEPRESSANT USE AND PREVALENT CHD
Table 4 describes results of analyses assessing the associa-
tion of antidepressant medications with prevalent CHD. Model
1 relates to the results of unadjusted analyses for antide-
pressant use [model χ2(1)= 7.12, p= 0.008] and antidepres-
sant class [model χ2(4)= 14.03, p= 0.007], while model 2
relates to results adjusted for covariates [antidepressant use,
Table 1 | Participant characteristics by CHD status (N =14,994).
Characteristics No CHD (n=14,284, 95%) CHD (n=710, 5%) Statistic
Age, mean (SD) 51.75 (8.97) 58.66 (8.74) t (14,992)=20.07, p<0.001
Women (%) 54.8 45.5 χ2(1)=23.45, p<0.001
Education (%) χ2(2)=85.16, p<0.001
Less than high-school 12.1 23.7*
High-school 34.8 33.8
College 53.1 42.5*
Smoker (past or current) (%) 42.5 56.1 χ2(1)=50.77, p<0.001
Body mass index (kg/m2), mean (SD) 26.95 (4.74) 28.37 (4.80) t (14,992)=7.76, p<0.001
Diabetes mellitus (yes) (%) 18.7 37.9 χ2(1)=157.21, p<0.001
Hypertension (yes) (%) 34.0 70.0 χ2(1)=382.49, p<0.001
Common mental disorder (yes) (%) 26.2 35.5 χ2(1)=29.86, p<0.001
CIS-R Score, mean (SD) 8.08 (7.86) 10.34 (9.61) t (756.82)=6.18, p<0.001
Antidepressant use (yes) (%) 6.0 8.6 χ2(1)=7.91, p=0.005
CIS-R, Clinical Interview Schedule-Revised. *Refers to categories with standardized residuals (z-scores) lying outside±1.96 reflecting a significance value of p<0.05.
Table 2 | Participant characteristics by antidepressant use (N =14,994).
Characteristics No (n=14,076, 94%) Yes (n=918, 6%) p-Value
Age, mean (SD) 51.97 (9.07) 53.70 (9.14) t (14,992)=5.59, p<0.001
Women (%) 52.9 76.4 χ2(1)=191.32, p<0.001
Education (%) χ2(2)=34.90, p<0.001
Less than high-school 13.0 7.8*
High-school 35.0 31.2
College 52.0 61.0*
Smoker (past or current) (%) 42.9 47.1 χ2(1)=6.15, p=0.013
Body mass index (kg/m2), mean (SD) 27.01 (4.75) 27.09 (4.76) t (14,992)=0.48, p=0.632
Diabetes mellitus (yes) (%) 19.8 17.8 χ2(1)=2.20, p=0.138
Hypertension (yes) (%) 35.6 36.5 χ2(1)=0.28, p=0.596
CHD status (yes) (%) 4.6 6.7 χ2(1)=8.39, p=0.004
Common mental disorder (yes) (%) 25.4 45.6 χ2(1)=180.59, p<0.001
CIS-R Score, mean (SD) 7.92 (7.75) 12.27 (9.90) t (991.68)=13.06, p<0.001
CIS-R, Clinical Interview Schedule-Revised. *Refers to categories with standardized residuals (z-scores) lying outside±1.96 reflecting a significance value of p<0.05.
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Table 3 | Participant characteristics by antidepressant grouping (N =14,994).
Characteristics CTL
(n=14,076)
SSRI
(n=567)
SNRI
(n=100)
TCA
(n=156)
Other
(n=95)
p-Value
Age, mean (SD) 51.97 (9.07) 53.70* (9.36) 55.48* (8.60) 53.42 (8.45) 52.26 (9.33) F (4,14,993)=9.41, p<0.001
Women,% 52.9* 77.8* 81.0* 75.0* 65.3 χ2(4)=197.48, p<0.001
Education (%) χ2(8)=80.32, p<0.001
Less than high-school 13.0 6.7* 4.0* 15.4 6.3
High-school 35.0 28.6* 23.0* 47.4* 28.4
College 52.0 64.7* 73.0* 37.2* 65.3
Smoker (past or current) (%) 42.9 47.1 40.0 47.4 53.7 χ2(4)=9.89, p=0.042
BMI (kg/m2), mean (SD) 27.01 (4.75) 27.12 (4.89) 27.68 (4.62) 26.83 (4.06) 26.69 (5.21) F (4,14,993)=0.731, p=0.571
Hypertension (yes)% 35.6 34.9 45.0 38.5 33.7 χ2(4)=4.64, p=0.33
Diabetes (yes)% 19.8 17.3 18.0 20.5 15.8 χ2(4)=3.27, p=0.51
CHD (yes) (%) 4.6 6.3 3.0 10.9* 5.3 χ2(4)=17.61, p=0.001
Common mental disorder (yes) (%) 25.4* 45.0* 43.0* 46.2* 51.6* χ2(4)=182.81, p<0.001
CIS-R Score, mean (SD) 7.92 (7.75) 12.17 (9.70)* 12.19 (10.51)* 12.48 (10.24)* 12.55 (9.94)* F (4,14,993)=65.42, p<0.001
*Refers to one-way ANOVA in which each group is compared to controls (Tukey’s HSD, p< 0.05) or standardized residuals (z-scores) from χ2 statistics lying
outside± 1.96 reflecting a significance value of p<0.05.
Table 4 | Unadjusted (model 1)a and adjusted (model 2)b associations between antidepressant use and CHD (N =14,994).
Predictor N CHD: model 1a (n=710) N CHD: model 2b (n=710)
OR 95% CI p-Value OR 95% CI p-Value
Any antidepressant use
No 14,076 REF 14,076 REF
Yes 918 1.47 1.12–1.93 0.005 918 1.28 0.96–1.71 0.093
Antidepressant groupings
None 14,076 REF 14,076 REF
SSRI 567 1.40 0.99–1.98 0.056 567 1.26 0.87–1.81 0.218
SNRI 100 0.64 0.20–2.02 0.447 100 0.47 0.15–1.52 0.209
TCA 156 2.53 1.52–4.21 <0.001 156 2.15 1.24–3.71 0.006
Other 95 1.15 0.47–2.84 0.763 95 1.03 0.40–2.65 0.949
aModel 1 relates to separate unadjusted analyses for any antidepressant use and specific classes of antidepressant including SSRI (selective serotonin reuptake
inhibitors), SNRI (serotonin and noradrenaline reuptake inhibitors), TCA (tricyclic antidepressants), and other.
bModel 2 relates to analyses adjusted for covariates.
model χ2(10)= 724.85, p< 0.001; block χ2(1)= 2.69, p= 0.101;
antidepressant class, model χ2(10)= 732.04, p< 0.001; block
χ2(4)= 9.88, p= 0.042]. Antidepressant use was associated with
a 1.5-fold increase in the odds of prevalent CHD (95% CI: 1.12–
1.93) (model 1), although this was reduced to a 1.3-fold increase
when adjusting for covariates (95% CI: 0.96–1.71) (model 2). Sen-
sitivity analysis revealed that use of TCAs (OR= 2.53, 95% CI:
1.52–4.21, model 1; OR= 2.15, 95% CI= 1.24–3.71) in particular
is significantly associated with prevalent CHD.
ASSOCIATION BETWEEN ANTIDEPRESSANT USE AND CHD SUBTYPES
Table 5 reports results for the additional specificity analy-
ses on stable angina pectoris [antidepressant use: model
χ2(10)= 223.26, p< 0.001; block χ2(1)= 0.02, p= 0.891; anti-
depressant class: model χ2(13)= 223.26, p< 0.001; block
χ2(4)= 3.02, p= 0.555], myocardial infarction [antidepressant
use: model χ2(10)= 426.90, p< 0.001; block χ2(1)= 0.83,
p= 0.361; antidepressant class: modelχ2(13)= 437.14,p< 0.001;
block χ2(4)= 11.07, p= 0.026], and coronary revasculariza-
tion [antidepressant use: model χ2(10)= 440.68, p< 0.001;
block χ2(1)= 6.02, p= 0.014; antidepressant class: model
χ2(13)= 448.41, p< 0.001; block χ2(4)= 13.75, p= 0.008].
While there were no significant associations observed for sta-
ble angina, use of tricyclic medications were associated with a
threefold increase in odds for myocardial infarction as well as coro-
nary revascularization. These additional findings indicate that the
association between TCA use and prevalent CHD is specific to
“hard” CHD events including myocardial infarction and coronary
revascularization.
DISCUSSION
The goal of this study was to determine the associations between
use of antidepressant medications and prevalent CHD in a cohort
of civil servants from Brazil. This is an important goal because
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Table 5 | Fully adjusted association between antidepressant use and CHD subtypes (N =14,994).
Predictor N Stable angina
(n=312)a
N Myocardial infarction
(n=267)
N Coronary
revascularization (n=255)
OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value
Any antidepressant use
No 13,715 REF 14,076 REF 14,076 REF
Yes 881 0.85 0.54–1.36 0.501 918 1.25 0.78–2.01 0.349 918 1.79 1.15–2.77 0.009
Antidepressant groupings
None 13,715 14,076 REF 14,076 REF
SSRI 546 1.00 0.58–1.71 0.989 567 1.12 0.59–2.10 0.735 567 1.96 1.16–3.34 0.013
SNRI 98 0.30 0.04–2.16 0.229 100 n/a n/a 0.996 100 1.15 0.27–4.85 0.845
TCA 143 1.01 0.37–2.79 0.986 156 2.96 1.41–6.21 0.004 156 2.92 1.28–6.66 0.011
Other 94 1.65 0.59–4.64 0.340 95 0.54 0.07–4.03 0.547 95 n/a n/a 0.996
aThis model excludes 398 participants with myocardial infarction or coronary revascularization.
Brazil currently faces many socioeconomic inequities, which may
impact on antidepressant usage. Major findings indicate that use
of TCA is associated with: (1) a twofold increase in the odds
for prevalent CHD and (2), a threefold increase in the odds for
myocardial infarction and coronary revascularization, after adjust-
ment for covariates. The associated 95% confidence intervals for
TCA use – all of which excluded the null value of 1 – provide sets
of likely values for the odds ratio on which for a repeated study
would most likely fall (on average, a five-in-six chance) (27). Val-
ues close to the sample estimates, however, are ~7 times more likely
to reflect the true population estimate (µ), than values near the
limits of the interval (27). These considerations and the size of the
effects obtained, enhance our confidence in the reported findings
reported here.
While our study highlights a strong relationship between TCA
use and “hard” CHD events, it is important to acknowledge that
some participants in our study may have been using low-dose
TCAs to treat conditions other than mental disorders, such as
chronic/neuropathic pain and sleep issues. Importantly, research
has demonstrated a dose-related increase in sudden cardiac death
in current users of TCAs from 0.97 for doses lower than 100 mg
(amitriptyline or its equivalent) to 2.53 for doses of 300 mg or
more, highlighting that doses of <100 mg does not increase risk
(at least for sudden cardiac death). However, current recommen-
dations indicate that TCAs should be avoided completely in cardiac
patients (7). In Brazil, access to TCAs is free (18, 19), while access
to other classes of antidepressants is restricted suggesting socioe-
conomic reasons that may increase the association between TCA
and prevalent CHD. It is notable that elderly Brazilian patients
with psychiatric disorders are 5.3 times more likely to be using
inappropriate medications (28). We suggest that these previous
findings (28) may help to understand the findings that we report
here, which may indicate problems associated with ongoing health
care of cardiac patients in the Brazilian population.
It is important to acknowledge the cross-sectional design as
an important limitation of the present study. This limitation pre-
cludes any conclusions over the causal relationship between TCA
use and CHD. For instance, it is equally possible that TCA use
preceded the development of CHD consistent with research that
suggests TCAs lead to cardiovascular events [e.g., Ref. (17)] (i.e.,
a biological explanation) beyond that explained by psychiatric
illness, or that TCAs were prescribed after CHD was diagnosed
consistent with research that suggests patients may be inappropri-
ately medicated in Brazil [e.g., Ref. (28)] (i.e., a sociodemographic
explanation). However, regardless of the causal direction of the
relationship between TCA use and CHD, our findings still have
important implications for the treatment of cardiac patients in
Brazil. It is notable here that research from the Netherlands (5),
a high-income country, did not observe a significant associa-
tion between use of TCAs and CHD. The authors noted that
while the adverse cardiovascular effects of TCAs are well known,
a null finding might reflect the contraindication of TCA use in
heart patients. We suggest here that socioeconomic inequities in
Brazil may over-ride recommendations to avoid these medica-
tions in cardiac patients as patients have easier and free access
to this class of antidepressant medications through free public
health care.
Longitudinal research (8) from the Netherlands Study of
Depression and Anxiety (N = 2,114) indicates that all classes of
antidepressants may have adverse effects on heart function, deter-
mined by reductions in heart rate variability, a psychophysiological
predictor of future cardiovascular mortality [see in Ref. (29) for
review]. Adverse effects were greatest for the TCAs, followed by the
SNRIs, and then the SSRIs, relative to no antidepressant use (8)
[see also in Ref. (30)]. This study also reported that these effects
disappear when antidepressants are discontinued. However, the
adverse effects reported for the SSRI class were small, which may, in
part, explain the contradictory findings reported previously for the
association between SSRIs and CHD (9, 17). SSRI antidepressants
are generally considered to have a more favorable cardiovascu-
lar profile than the TCA (and the serotonin and noradrenaline
reuptake inhibitors, or SNRIs). The SSRIs may exert cardiovas-
cular benefits through direct action on the biological substrates
of the stress response (31), including a blunting of blood pres-
sure, myocardial responses, and cortisol reactivity under stress.
The SSRIs also have antiplatelet properties, which will reduce the
risk for thrombus formation (2, 3). While we did not observe a
relationship between SSRIs and prevalent CHD, we did observe
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a twofold increase association for SSRIs and coronary revascular-
ization. A possible explanation for the null association between
SSRIs and myocardial infarction is the restricted access to antide-
pressants from the SSRI class of antidepressants, resulting perhaps
from the socioeconomic inequities of Brazilian mental health care
(28, 32, 33) and high cost of these newer medications.
In conclusion, the present study provides important new infor-
mation on the association of antidepressant use and prevalent
CHD in Brazil. While a limitation of our study is its cross-sectional
design, this limitation does not undermine the importance of
our findings, as TCA use in patients with CHD increases risk of
future morbidity and mortality. While it is possible that some
of our participants were on low-dose TCAs for conditions other
than depression and anxiety, recommendations from high-income
countries suggest that these medications should be avoided in car-
diac patients. Our study is characterized by a number of strengths
including a focus on a relatively large and well-characterized sam-
ple of the Brazilian population, application of a structured clinical
interview to determine psychiatric diagnosis and disorder sever-
ity, and adjustment for a host of covariates known to contribute to
metabolic and cardiovascular risk. Our findings indicate a strong
relationship between TCA use and prevalent CHD. We will fur-
ther examine the impact of the different antidepressant classes in
a longitudinal follow-up study of the ELSA-Brasil cohort once data
collection is complete.
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